Related references
Note: Only part of the references are listed.Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
Louis D. Saravolatz et al.
CLINICAL INFECTIOUS DISEASES (2023)
Insights for COVID-19 in 2023
Francisco Javier Martin-Sanchez et al.
REVISTA ESPANOLA DE QUIMIOTERAPIA (2023)
Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic
Nobuyuki Horita et al.
JOURNAL OF MEDICAL VIROLOGY (2023)
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
Taweegrit Siripongboonsitti et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)
Risk of Death in Individuals Hospitalized for COVID-19 With and Without Psychiatric Disorders: An Observational Multicenter Study in France
Nicolas Hoertel et al.
BIOLOGICAL PSYCHIATRY: GLOBAL OPEN SCIENCE (2023)
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls
Martina Calusic et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial
Chuan Huan Chuah et al.
CLINICAL INFECTIOUS DISEASES (2022)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Gilmar Reis et al.
LANCET GLOBAL HEALTH (2022)
Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
Christina M. Guo et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2022)
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization A Systematic Review and Meta-analysis
Todd C. Lee et al.
JAMA NETWORK OPEN (2022)
Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
Hyeonji Seo et al.
INFECTION AND CHEMOTHERAPY (2022)
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
Nicolas Hoertel et al.
MOLECULAR PSYCHIATRY (2021)
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
David Seftel et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Shuntai Zhou et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Tomiko Oskotsky et al.
JAMA NETWORK OPEN (2021)
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Vikas P. Sukhatme et al.
FRONTIERS IN PHARMACOLOGY (2021)
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
Soheil Hassanipour et al.
SCIENTIFIC REPORTS (2021)
FLUOXETINE USE IS ASSOCIATED WITH IMPROVED SURVIVAL OF PATIENTS WITH COVID-19 PNEUMONIA: A RETROSPECTIVE CASE-CONTROL STUDY
Zsofia Klara Nemeth et al.
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE (2021)
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
J. Homolak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
Dhan Bahadur Shrestha et al.
VIROLOGY JOURNAL (2020)
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial
Eric J. Lenze et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus
To Sing Fung et al.
VIROLOGY (2019)